Evelo Biosciences Statistics
Share Statistics
Evelo Biosciences has 18.98M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 18.98M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.4% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 196.99K, so undefined% of the outstanding
shares have been sold short.
| Short Interest | 196.99K |
| Short % of Shares Out | n/a |
| Short % of Float | 1.18% |
| Short Ratio (days to cover) | 0.12 |
Valuation Ratios
The PE ratio is -1.23 and the forward
PE ratio is null.
Evelo Biosciences's PEG ratio is
0.03.
| PE Ratio | -1.23 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -28.11 |
| P/FCF Ratio | -1.38 |
| PEG Ratio | 0.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Evelo Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.16,
with a Debt / Equity ratio of -10.24.
| Current Ratio | 4.16 |
| Quick Ratio | 4.16 |
| Debt / Equity | -10.24 |
| Debt / EBITDA | -0.48 |
| Debt / FCF | -0.5 |
| Interest Coverage | -23.22 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,735,257.58 |
| Employee Count | 66 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 930K |
| Effective Tax Rate | -0.82% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 1.07, so Evelo Biosciences's
price volatility has been higher than the market average.
| Beta | 1.07 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0 |
| 200-Day Moving Average | 0 |
| Relative Strength Index (RSI) | 32.75 |
| Average Volume (20 Days) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -108.47M |
| Net Income | -114.53M |
| EBITDA | -106.34M |
| EBIT | -108.92M |
| Earnings Per Share (EPS) | -26.28 |
Full Income StatementBalance Sheet
The company has 47.94M in cash and 51.14M in
debt, giving a net cash position of -3.2M.
| Cash & Cash Equivalents | 47.94M |
| Total Debt | 51.14M |
| Net Cash | -3.2M |
| Retained Earnings | -529.22M |
| Total Assets | 20.63M |
| Working Capital | -20.82M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -101.23M
and capital expenditures -622K, giving a free cash flow of -101.86M.
| Operating Cash Flow | -101.23M |
| Capital Expenditures | -622K |
| Free Cash Flow | -101.86M |
| FCF Per Share | -23.37 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
